Mon, Oct 16th 2023
Lonza has won another customer for its biopharmaceutical production complex “Ibex” in Visp. The pharmaceutical supplier is cooperating with the US company Vaxcyte in the development of vaccine candidates against pneumococcal diseases.
Lonza said on Monday the agreement includes potential global commercialisation of candidates VAX-24 and VAX-31. Under the terms of the agreement, Lonza will provide Vaxcyte with a “customised” manufacturing suite.
Construction of the facility is nearly complete, it said, and installation of the devices will begin in 2024. Upon reaching peak capacity, Lonza will create up to 300 new jobs, it added. Financial details of the agreement were not disclosed.
Lonza has thus won its next contract in Visp after the loss of the Corona vaccine production for the US company Moderna. Already at the beginning of October, the cooperation with an existing customer in the field of antibody-drug conjugates (ADC) was extended. Thanks to this order, around 180 jobs will be created.
©Keystone/SDA
English 
German 
French 
Spanish 
Arabic